Orexo AB (ORX) Fair Value & Analysis
Healthcare · SE · Market cap 667M SEK
Fair value as of: Jun 24, 2026
From 7 valuation models · updated 6 days ago
Share price +17.1% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 16.88 – kr 39.00 · fair‑value band kr 47.14 – kr 78.56 · the kr 22.50 price screens below the kr 62.85 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Orexo AB (ORX) currently trades at kr 22.50, while our model-based Fair Value estimate is kr 62.85 — implying the stock looks roughly 179.3% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at 17.8M SEK. Revenue declined 62.1% year over year. The balance sheet holds a net cash position of 420M SEK. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Orexo AB reported revenue of kr 26.0M in FY2025 versus kr 565M in FY2021, a compound −53.7%/yr. Reported net income was −kr 130M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Orexo AB (ORX) undervalued?
What is the fair value of ORX?
What is the quality score of ORX?
What is the revenue of Orexo AB (ORX)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.